orismilast topical (LEO 32731 topical) / LEO Pharma, UNION Therap, Innovent Biologics - LARVOL DELTA

A lower dose of orismilast may pave the way for new treatments for HD [Google Translation] - "'Orismilast can be a drug to treat hidrosadenitis suppurativa with, which is why we have investigated the side effects in more detail,' says Gregor Jemec....'Previous studies have shown that treatment with apremilast had little effect on the disease. Treatment with orismilast has shown a slightly greater effect, but has also shown a number of gastrointestinal side effects. We have therefore investigated whether the dose can be adjusted so that the patients can tolerate the treatment and still see an effect,' says Gregor Jemec."

Media quote • Hidradenitis Suppurativa

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions (PRNewswire) - "Innovent Biologics...and UNION therapeutics A/S (UNION)...announced that they have entered into a strategic collaboration and license agreement for the development and commercialization of orismilast in China. Under the terms of the agreement, UNION grants Innovent an exclusive license to research, develop and commercialize orismilast in China, including participating in and recruiting Chinese patients for potential future global studies of orismilast. UNION will receive an upfront payment of USD 20 million and is further entitled to receive up to USD 247 million in milestone payments as well as tiered royalties on sales of orismilast in China. UNION will retain global rights for orismilast outside of China."

Licensing / partnership • Atopic Dermatitis • Immunology • Psoriasis